23andMe quietly builds a clinical trial recruitment business

October 03, 2019
Digital Transformation More...
by Nardev Ramanathan
Very important

23andMe has been quietly working for months on its clinical trial recruitment business by emailing customers who've opted in with recommendations about clinical studies they could be part of. It has recruited for studies in disease areas including Alzheimer's, Parkinson's, and liver disease. This press release further solidifies 23andMe's intent to leverage its massive database of some 10 million consumers catered toward pharma (who are hungry for real-world genomic data) in developing precision therapies. This is interesting and one of the first such strategic shifts by a consumer genomics company we've seen, and it highlights the opportunity genomic data can present for clients, especially in Asia, where a large gap still remains.

For the original news article, click here .

Further Reading

Major drugmaker GSK leverages 23andMe's consumer genomic database for its drug development strategy

Case Study | September 21, 2018

The cost of developing a new pharmaceutical drug today and successfully bringing it to market is approximately $2.5 billion, double what it used to be a decade ago. The steep rise in costs comes despite an intense effort in recent years to bring efficiency to pharmaceutical R&D. Assessing this ... Not part of subscription

Freenome raises $160 million for its AI-enabled early-stage colorectal cancer detection test

News Commentary | August 01, 2019

While the race to develop liquid biopsy tests has become increasingly competitive, Freenome's strategy is unique in that its platform analyzes both tumor‑ and immune‑derived signatures, which could aid in early‑stage cancer detection where signals from a tumor itself are faint. Improving diagnostics... Not part of subscription

AI for drug discovery company BenevolentAI cuts $2 billion valuation in half in recent funding round

News Commentary | September 25, 2019

The company reportedly raised $90 million from Singapore‑based Temasek at a $1 billion valuation, down from $2 billion in just 2018. As Lux previously described, the company made bold claims about its technology and overstated the current capabilities of AI. Clients should recognize the long‑term ... Not part of subscription